BMT CTN Protocol 1202

Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT.

Below are protocol-related documents, which may be periodically updated.

             Protocol Co-Chair: John Levine, MD (734-936-8456)

             Protocol Co-Chair: John Hansen, MD

             Protocol Officer: Wael Saber, MD

             Protocol Coordinator: Dylan Mawby (301-251-1161)

             Medical Monitor: Wael Saber, MD



The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study.